- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant
- Interventions
- ST-920
- Biological
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2039
- U.S. locations
- 8
- States / cities
- Irvine, California • Tampa, Florida • Atlanta, Georgia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 13,084
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Operator Radiation Exposure
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Atlanta, Georgia • Rochester, Minnesota + 1 more
- Conditions
- Melanoma, Malignant Metastatic Melanoma
- Interventions
- MEDI--522, Integrin + Dacarbazine
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Long Beach, California • San Francisco, California + 20 more
- Conditions
- Essential Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Scottsboro, Alabama + 47 more
- Conditions
- Cancer, Early Detection of Cancer, Minimal Residual Disease
- Interventions
- Not listed
- Lead sponsor
- Caris Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2035
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 32 more
- Conditions
- Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
- Interventions
- Everolimus 10 mg, Octreotide Depot
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- HIV-1
- Interventions
- DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Not listed
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 27
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin, LY2189265, Placebo (oral), Placebo (subcutaneous)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Buena Park, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- CVL-751
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Long Beach, California • Atlanta, Georgia
- Conditions
- Stress Disorders, Post-Traumatic, Substance Use Disorders
- Interventions
- Prolonged Exposure Therapy
- Behavioral
- Lead sponsor
- Veterans Medical Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- San Diego, California • Tampa, Florida • Atlanta, Georgia + 3 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Solid Tumors
- Interventions
- Casdatifan, Cabozantinib, Zimberelimab, Ipilimumab, Tivozanib, Ivonescimab, Axitinib
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic factor, recombinant, manufactured protein-free
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more
- Conditions
- Patients at Risk for Developing Contrast-induced Nephropathy
- Interventions
- DyeVert™ Contrast Reduction Systems
- Device
- Lead sponsor
- Osprey Medical, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Hartford, Connecticut • Hialeah, Florida • Atlanta, Georgia + 7 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Fomivirsen sodium
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Irvine, California • Los Angeles, California • Pasadena, California + 19 more
- Conditions
- Myelodysplastic Syndrome
- Interventions
- eltrombopag olamine, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more
- Conditions
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Stroke
- Interventions
- Telerehabilitation
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 27
- States / cities
- Downey, California • Irvine, California • Los Angeles, California + 20 more
- Conditions
- Type 1 Diabetes
- Interventions
- Omnipod 5 System
- Device
- Lead sponsor
- Insulet Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more
- Conditions
- Fragile X Syndrome
- Interventions
- Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 13 Years to 45 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Irvine, California • Orange, California + 12 more
- Conditions
- Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
- Interventions
- IPI-504, Trastuzumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 10
- States / cities
- Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more
- Conditions
- ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Pembrolizumab, Radiation Therapy
- Biological · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 114
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
- Conditions
- Chronic Ischemic Stroke
- Interventions
- SB623 Implant (2.5M), SB623 Implant (5.0M), Sham surgery
- Biological · Procedure
- Lead sponsor
- SanBio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Carlsbad, California + 43 more